ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2025
Quality of life, sexual function and metabolic parameters of women during 10 years of using the etonogestrel implant.
Article in European journal of obstetrics & gynecology and reproductive biology: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the effects on the quality of life (QoL), sexual function and metabolic aspects in women using a subcutaneous implant containing Etonogestrel (ENG-implant) over 10 years of observation period. Study design: This study was performed from January 2011 to September 2023. A database was set up to collect data from women. Counseling on the ENG-implant to be inserted at the termination of pregnancy, and on insert a new device every 3 years was adopted. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) questionnaires were used to investigate the QoL, sexual function and sexual distress, respectively, of women at baseline and at 6, 12, 24, 36, 72 and 108-month follow-ups. Blood samples were collected from women to measure metabolic parameters. Results: 32 of 52 (61.5 %) enrolled women completed the study. In summary, after removing the first (at 36th month of use) and the second implant (at 72nd month of use), 44 (84.6 %) and 32 (61.5 %) women asked for the insertion of a new device, respectively. Somatic (p < 0.001) and mental (p = 0.04) categories of SF-36 improved from the 12-month follow-up to the 108-month follow-up (p < 0.001). FSFI scores also increased from 12-month follow-up to the 108-month follow-up (p < 0.001). The improvement of the total scores depended on the gradual increase in each FSFI item (p < 0.001).FSDS score became statistically significant starting from the 12-month follow-up to the 108-month follow-up (p < 0.001). Although lipid metabolism, fasting glucose, liver function and hemostatic parameters were slightly reduced, they remained within the range of the normal values. Conclusions: The long observation period of 10 years allowed us to state that the ENG-implant could have neutral effects on metabolic parameters, promote a better quality of life, and improve sexuality in the users. The main limitation of our study was the small number of women enrolled, mainly due to the cost of the implant. These results should be confirmed on a larger sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.